What is Pfizer patient assistance program?
Pfizer Patient Assistance Program Provides free Pfizer medicines to eligible patients through their doctor's office or at home.
What is Xelsource?
Psoriatic Arthritis. • XELJANZ/XELJANZ XR (tofacitinib) is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
What does XELJANZ treat?
XELJANZ (tofacitinib) is the first approved pill of its kind (JAK inhibitor) that treats adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderate to severe ulcerative colitis.
How do I contact eliquis?
Call 1-855-ELIQUIS (354-7847) or click below to see if you are eligible to have samples delivered to your office.
Does tofacitinib cause hair loss?
Official answer. Hair loss is not a side effect of Xeljanz (tofacitinib citrate), according to the results of clinical trials used to gain approval of the drug. During clinical development, hair loss was not reported as an adverse effect.
Does Xeljanz work for ulcerative colitis?
XELJANZ is the first and only FDA-approved pill for adults with moderate to severe ulcerative colitis (UC) in whom tumor necrosis factor (TNF) blockers did not work well or cannot be tolerated.
How long can you stay on Xeljanz?
Ulcerative Colitis Xeljanz 10 mg twice daily for at least eight weeks; then 5 mg twice daily. A higher dose of 10 mg twice daily can be continued for a total of 16 weeks, depending on response.
What are the serious side effects of Xeljanz?
Serious side effects* of Xeljanz and Xeljanz XR may include:tears in your digestive tract.blood disorders.cardiovascular problems, such as heart attack or stroke.risk of serious infections†risk of blood clots†risk of cancer and immune system disorders†risk of death in certain people†allergic reaction.
What can I take instead of Xeljanz?
There are currently no generic alternatives to Xeljanz in the United States. Fortunately, Natco Pharma, an Indian pharmaceutical company, launched a generic Xeljanz (tofacitinib) called Jaknat 5 mg recently, which can help you save up to 90%.
What is a cheaper alternative to Eliquis?
Warfarin (Coumadin, Jantoven). Warfarin is a comparable generic drug that can cost as little as $4 with a GoodRx discount.
Is there a class action lawsuit against Eliquis?
The Eliquis class action links the drug to bleeding complications including bleeding in the brain, intestinal bleeding, kidney bleeding, uncontrolled bleeding, deep vein thrombosis (DVT), and death. The drug has been on the market since 2012, and is manufactured by Pfizer and Bristol-Meyers Squibb.
How do seniors pay for Eliquis?
Medicare typically covers Eliquis through Medicare Advantage Part C or Medicare Part D prescription drug coverage plans. Eliquis is a brand name for apixaban, a prescription oral anticoagulant tablet.
Does Xeljanz cause weight gain or weight loss?
Does Xeljanz cause weight gain or weight loss? No, Xeljanz and Xeljanz XR don't lead to weight gain or weight loss. But serious side effects of these drugs or your condition itself may cause unexplained weight loss. For example, weight loss can be seen with diarrhea, serious infection, and cancer.
Is Xeljanz a high risk medication?
Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib) The FDA has issued new information about Xeljanz, Xeljanz XR (tofacitinib) and other Janus kinase (JAK) inhibitors.
What is the difference between Humira and Xeljanz?
Xeljanz and Humira belong to different drug classes. Xeljanz is a Janus kinase (JAK) inhibitor and Humira is a tumor necrosis factor (TNF) blocker. Side effects of Xeljanz and Humira that are similar include headache and stuffy nose.
Does Xeljanz grow hair?
Researchers found that more than 50 percent of 66 patients treated with the drug Xeljanz (tofacitinib citrate) saw hair regrowth in three months.